Download PDF
Thromb Haemost 1970; 24(01/02): 265-272
DOI: 10.1055/s-0038-1654233
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Studies on the Anticoagulant Action of Aprotinin (“Trasylol”)[*]

C. R. M Prentice M. R. C. P.
1   University Department of Medicine, Royal Infirmary, Glasgow, C.4
,
G. P McNicol M. D., Ph. D., F. R. C. P. (Ed., Glasgow)
1   University Department of Medicine, Royal Infirmary, Glasgow, C.4
,
A. S Douglas M. D., F. R. C. P. (Lond., Ed., Glasg.)
1   University Department of Medicine, Royal Infirmary, Glasgow, C.4
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

Studies were undertaken to localize the site of the anticoagulant action of Aprotinin (“Trasylol”). Contact activation studies using either kaolin or contact product eluted from celite demonstrated that Aprotinin had greatest inhibitory action against the interaction of a surface with the contact factors, but some inhibition of formed contact product was also noted. In addition, Aprotinin was found to have a slight anticoagulant action against activated factor IX prepared by incubation of contact product with a calcium phosphate eluate from serum. No inhibitory action in pharmacological doses was demonstrated against activated factor X or later stages in the coagulation sequence.

It was concluded that Aprotinin is a relatively weak anticoagulant in doses liable to be obtained in vivo during therapeutic infusions.

* The work conducted by C.R. M. Prentice has been supported by a grant from the Medical Research Council.


 

  • References

  • 1 Amris G. J. Inhibition of fibrinolytic and thromboplastic activity by Trasylol. Scand. J. Haemat 03: 19 1966;
    PubMedSearch in Google Scholar
  • 2 Amris G. J, Hilden M. Inhibition of thromboplastic activity by Trasylol. Scand. J. Haemat 04: 3 1967;
    PubMedSearch in Google Scholar
  • 3 Beck E, Schmutzler R, Duckert F. Inhibition of fibrinolysis and fibrinogenolysis in man: comparison of E-aminocaproic acid and kallikrein inhibitor. Thrombos. Diathes. haemorrh. (Stuttg) 10: 106 1963;
    PubMedSearch in Google Scholar
  • 4 Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path 06: 23 1953;
    CrossrefPubMedSearch in Google Scholar
  • 5 Biggs R, Nossel H. L. Tissue extract and the contact reaction in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg) 06: 1 1961;
    PubMedSearch in Google Scholar
  • 6 Blombäck B, Blombäck M, Olsson P. Action of a proteolytic enzyme inhibitor on blood coagulation in vitro. Thrombos. Diathes. haemorrh. (Stuttg) 18: 190 1967;
    PubMedSearch in Google Scholar
  • 7 Dubber A. HG, McNicol G. P, Uttley D, Douglas A. S. In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor. Brit. J. Haemat 14: 31 1968;
    CrossrefPubMedSearch in Google Scholar
  • 8 Gormsen J, Josephsen P. The effect of Trasylol on blood coagulation after intravenous injection. Thrombos. Diathes. haemorrh. (Stuttg) 17: 51 1967;
    PubMedSearch in Google Scholar
  • 9 Henderson E. S, Rapaport S. I. The thrombotic activity of activation product. J. clin. Invest 41: 235 1962;
    CrossrefPubMedSearch in Google Scholar
  • 10 Mammen E. F. Ann. N.Y. Acad. Sci. 146: 713 1968;
    PubMedSearch in Google Scholar
  • 11 Marx von R, Clemente P, Werle E, Appel W. Über die Wirkung von ProteinaseinhibitorPräparaten (Leber- und Parotisinhibitor) auf die extravasale Fibrinolyse, Fibrinogenolyse und Blutgerinnungskonstanten im Menschenblut. Blut 09: 164 1963;
    CrossrefPubMedSearch in Google Scholar
  • 12 Nordstrom S, Blombäck B, Blombäck M, Olsson P, Zetterquist E. Experimental investigations on the antithromboplastic and antifibrinolytic activity of Trasylol. Ann. N.Y. Acad. Sci 146: 701 1968;
    CrossrefPubMedSearch in Google Scholar
  • 13 Nordstrom S, Olsson P, Blombäck M. Thromboplastin-induced hypercoagulability and its prevention. Nature (Lond) 206: 632 1965;
    PubMedSearch in Google Scholar
  • 14 Nossel H. L. The Contact Phase of Blood Coagulation. Ch. 7. Blackwell; Oxford: 1964
    Search in Google Scholar
  • 15 Nossel H. L. The Contact Phase of Blood Coagulation. 50 Blackwell; Oxford: 1964
    Search in Google Scholar
  • 16 Owren P. A. A quantitative one-stage method for the assay of prothrombin. Scand. J. clin. Lab. Invest 01: 81 1949;
    CrossrefPubMedSearch in Google Scholar
  • 17 Prentice C. RM, Ratnoff O. D, Breckenridge R. T. Experiments on the nature of the prothrombin-converting principle : alteration of proaccelerin by thrombin. Brit. J. Haemat 13: 898 1967;
    CrossrefPubMedSearch in Google Scholar
  • 18 Proctor R. R, Rapaport S. I. The partial thromboplastin time with kaolin. Amer. J. clin. Path 36: 212 1961;
    PubMedSearch in Google Scholar
  • 19 Rapaport S. I, Hjort P. F, Patch M. J, Jeremic M. Consumption of serum factors and prothrombin during intravascular clotting in rabbits. Scand. J. Haemat 03: 59 1966;
    PubMedSearch in Google Scholar
  • 20 Ratnoff O. D, Davie E. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI). Biochemistry 01: 677 1962;
    CrossrefPubMedSearch in Google Scholar
  • 21 Steichele D. F, Herschlein H. J. Zur antifibrinolytischen Wirkung des Trypsin-Kallikrein- Inactivators. Med. Welt 1961; 2170.
    PubMedSearch in Google Scholar
  • 22 Wessler S, Reimer S. M. The role of human coagulation factors in serum-induced thrombosis. J. clin. Invest 39: 262 1960;
    CrossrefPubMedSearch in Google Scholar